Treats multiple inflammatory nodules with a diameter of 5 mm or greater. ANDA 218194, held by Aurobindo Pharma. Isotretinoin.
As of Nov 16, 2026, ANDA 218194 (Isotretinoin), held by Aurobindo Pharma, was first approved by FDA on Jan 29, 2024, with 4 approved supplements and 0 published complete response letters.
Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, isotretinoin capsules are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use If a second course of isotretinoin capsules treatment is needed, it is not recommended before a 2-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2024 | Original application | Approved | None posted |
| Isotretinoin10MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin20MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin25MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin30MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin35MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin40MG · capsule;oral | Isotretinoin | Rx |
| Nov 3, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 3, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 7, 2026 | Supplement 6REMS | Approved | None posted |
| Feb 9, 2026 | Supplement 1REMS | Approved | None posted |
| Jan 29, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters